Lexicon Pharmaceuticals (LXRX) Posts Narrower than Expected Q2 Loss of 5c/Sh.
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.18 --0%
EPS Growth %: -50.0%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -50.0%
Financial Fact:
Other income (expense), net: 564K
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
Lexicon Pharmaceuticals (NASDAQ: LXRX) reported Q2 EPS of ($0.05), $0.01 better than the analyst estimate of ($0.06). Revenue for the quarter came in at $555 thousand versus the consensus estimate of $350 thousand.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
For earnings history and earnings-related data on Lexicon Pharmaceuticals (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Paychex (PAYX) Tops Q1 EPS by 2c
- Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
- AppLovin drops 3% as Edgewater analyst warns of stalled market share growth
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
